Academic Health Center
Stay Connected
research-and-clinical-trials

U of M research finds kava plant may prevent cigarette smoke-induced lung cancer

New research from the University of Minnesota College of Pharmacy and Masonic Cancer Center has found that consumption of the root of Piper methysticum, or kava, a plant native to the South Pacific Islands, may prevent the development of tobacco smoke-induced lung cancer.

Read more
research-and-clinical-trials

Research Snapshot: Seeking complete remission prior to allogeneic hematopoietic transplantation in patients battling AML

Allogeneic hematopoietic transplantation (allo-HCT) is one of the most advanced cell-based therapies available in the fight against complex conditions that can damage or disrupt bone marrow or immune system function.

The procedure, which involves a transplant of blood-forming stem cells from a donor with genetic similarities, provides patients a chance for remission in the fight against conditions like multiple myeloma, non-Hodgkin lymphoma and several types of acute and chronic leukemias, to name a few.

The procedure also remains one of the most effective treatments for most patients with acute myeloid leukemia (AML).

But what conditions should physicians see in their patients before employing allo-HCT?

Read more
research-and-clinical-trials

U of M researchers identify key proteins influencing major immune strategy

New research from the Masonic Cancer Center, University of Minnesota, and the University of Minnesota Center for Immunology has identified key proteins that influence immune response strategies, a finding that could influence new vaccination approaches.

The study, published in the latest edition of Nature Immunology, looked closely at the KLF2 and S1P1 genes, and how their expression impacted the immune strategy of a cell.

Read more
research-and-clinical-trials

First pre-surgical breast cancer drug gets FDA approval

The FDA has just given approval to a biotech drug from Roche to be used as a pre-surgical treatment for one of the deadliest forms of breast cancer.

The drug, known as Perjeta, has doctors hoping they can shrink tumors earlier, making them easier to remove. This would allow more women to keep their breasts instead of pursuing a full mastectomy, as well as increase positive outcomes for patients…

Read more
research-and-clinical-trials

U of M looks to new breast cancer drug to propel current research

Douglas Yee, M.D., a University of Minnesota Physicians breast cancer specialist and director of the Masonic Cancer Center appeared on Fox 9 earlier this week to discuss a new drug that combats breast cancer in its earliest stages, a major milestone for researchers and patients alike.

Read more
research-and-clinical-trials

Research Q&A: Identifying cancer’s source

In a case of “what caused the cancer?” University of Minnesota scientists are aiming to find out if diet or environmental exposures to hazardous chemicals from a person’s past can be linked to a patient’s cancer today.

Health Talk recently sat down to discuss a noteworthy discovery made in the lab of researcher Robert Turesky, Ph.D., and postdoctoral fellow Byeong Hwa Yun, Ph.D., while the tandem were at the New York State Department of Health’s Wadsworth Center.

Turesky and Yun recently joined the Masonic Cancer Center, University of Minnesota, research team. Turesky is also a University of Minnesota College of Pharmacy professor.

Read more